Robert Lakin

Robert Lakin

InvestorPlace Contributor

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

NIO Stock: One Big Reason Nio Is Climbing Higher Today

By Robert Lakin, InvestorPlace Contributor

NIO stock is on the move as the EV maker looks poised to enter European markets. Q4 results are due out after markets close on Monday.

DYNT Stock: Why Little-Known Dynatronics Is Soaring 90% Today

By Robert Lakin, InvestorPlace Contributor

DYNT stock hit a low in November as demand for its rehab products faded with cancelled elective surgical procedures. Now, with vaccines on the rise, patients are scheduling what they earlier postponed.

KOSS Stock: Why Reddit-Favorite Koss Is Rocketing Higher Today

By Robert Lakin, InvestorPlace Contributor

KOSS stock is making lots of noise as shares double in value. All signs point to the r/WallStreetBets crowd as the fuel for the surge.

FSR Stock: What to Know as Fisker Launches a New Electric Vehicle

By Robert Lakin, InvestorPlace Contributor

FSR stock is on the move today after announcing plans to develop another electric vehicle with Foxconn. Here's what to know.

RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today

By Robert Lakin, InvestorPlace Contributor

Shares of little-known biopharma firm Relief Therapeutics gained on clinical trials news. Names like RLFTF stock are in focus as investors shifting from vaccine makers to therapeutics as the pandemic rolls into its second year.

Load More